General Perspective

Bronchoscopic lung cryobiopsy: An Indian Association for Bronchology position statement


Departments of Pulmonary Medicine, 2Department of Pulmonary Medicine, Jindal Chest Clinic, Chandigarh, 3Department of Pulmonary Medicine, Jaipur Golden Hospital and Rajiv Gandhi Cancer Institute, 4Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, 5Department of Respiratory Medicine, Indraprastha Apollo Hospital, 6Department of Respiratory Medicine, Sir Ganga Ram Hospital, 7Department of Respiratory Medicine, Maharaja Agrasen Hospital, 8Department of Respiratory Medicine, Max Hospital, 9Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, 10Department of Respiratory Medicine, Fortis Hospital, 11Department of Respiratory Medicine, BLK Super Speciality Hospital, New Delhi, 12Department of Respiratory Medicine, Bombay Hospital and Fortis Hirmandani Hospital, 13Department of Respiratory Medicine, Nanavati Super Speciality Hospital, 14India and Lung Care and Sleep Centre, Institute of Pulmonology, Medical Research and Development, Mumbai, 15Department of Respiratory Medicine, Getwell Hospital and Research Institute, Nagpur, Maharashtra, 16Department of Respiratory Medicine, Postgraduate Institute of Medical Sciences, Rohtak, Haryana, 17Department of Chest Diseases, SMS Medical College, 18Department of Respiratory Medicine, Ashima Bhawan, Jaipur, Rajasthan, 19Department of Respiratory Medicine, Century Hospital, Hyderabad, Telangana, 20Department of Respiratory Medicine, Royal Care Hospital, Coimbatore, 21Department of Respiratory Medicine, Christian Medical College, Vellore, 22Department of Respiratory Medicine, Apollo Hospital, Chennai, Tamil Nadu, 23Department of Respiratory Medicine, Fortis Hospital Anandapur, Kolkata, West Bengal, 24Department of Respiratory Medicine, Narayana Health City, 25Department of Respiratory Medicine, Apollo Hospital, Bengaluru, Karnataka, 26Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, 27Department for Respiratory Diseases, Noida, Uttar Pradesh, 28Department of Internal and Pulmonary Medicine, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, 29Fortis Hospital, Mohali, Punjab, 30Department of Respiratory Medicine, City Clinic and Bhailal Amin General Hospital, Vadodara, Gujarat, India, 31Department of Medicine, Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, Texas, United States of America

ABSTRACT

Background: Bronchoscopic lung cryobiopsy (BLC) is a novel technique for obtaining lung tissue for the diagnosis of diffuse parenchymal lung diseases. The procedure is performed using several different variations of technique, resulting in an inconsistent diagnostic yield and a variable risk of complications. There is an unmet need for standardization of the technical aspects of BLC. Methodology: This is a position statement framed by a group comprising experts from the fields of pulmonary medicine, thoracic surgery, pathology, and radiology under the aegis of the Indian Association for Bronchology. Sixteen questions on bronchoscopic lung cryobiopsy are answered in this position statement. This document is intended to set the stage for planned future research to optimize the use of BLC in clinical practice. Address for correspondence: Dr. Ritesh Agarwal, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012, India. E-mail: agarwal.ritesh@outlook.in

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

INTRODUCTION

Diffuse parenchymal lung diseases (DPLDs) or interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by varying degrees of inflammation and fibrosis of the lung parenchyma.[1] A combination of clinical, radiological, and histological features is required to make a diagnosis of DPLD during a multidisciplinary discussion (MDD).[2–4] Bronchoalveolar lavage and conventional transbronchial biopsy (TBLB) are minimally invasive techniques for obtaining cytological/histopathological samples in DPLDs.[5–8] However, both are associated with a low accuracy in the diagnosis of most DPLDs.[9–11] Surgical lung biopsy (SLB) is considered the reference standard for providing lung tissue for the histologic examination in DPLD.[11] However, SLB is fraught with several limitations. It is an invasive procedure with significant mortality (pooled mortality of 3.6%) and a generally high (pooled yield, 95%) yet variable diagnostic yield (42%–100%).[12] Importantly, expertise in SLB, especially video-assisted thoracoscopic surgery (VATS), may not be available, particularly in resource-constrained settings.[13]

Bronchoscopic lung cryobiopsy (BLC) is a novel bronchoscopic technique of obtaining lung biopsy [Figure 1].[14,15] It involves the bronchoscopic placement of a flexible cryoprobe inside the lung parenchyma, freezing the probe and shearing out the lung tissue frozen around the tip. BLC yields tissue specimen larger than the conventional TBLB, resulting in a significantly higher diagnostic yield.[16] However, there is a caveat. There is no prospective, randomized trial comparing BLC with conventional TBLB performed with a large (7.3 mm cusp), fenestrated, alligator forceps. Most studies have used small (5 mm) nonfenestrated, cup forceps to obtain TBLB which may have spuriously led to a lower yield compared to BLC.[16] If BLC is not available, in selected cases, a conventional TBLB using a large alligator, fenestrated forceps may be performed.

Several centers across the world have reported the yield and safety of BLC in patients with DPLD.[17–21] However, there is no uniformity in the procedural aspects of BLC, which partially explains the varying yield and complications of the procedure. Several centers in India have also started performing this procedure with different methods.[22] Standardizing the method for performing BLC will ensure that the procedure is performed safely and effectively.[23] To address this unmet need, the Indian Association for Bronchology formed an expert group from the specialties of pulmonary medicine, thoracic surgery, radiology, and pathology from different parts of the country. This article is a position statement describing the technical aspects of BLC in the diagnosis of DPLDs.

METHODOLOGY

A systematic search of PubMed and EMBASE databases was performed for articles describing the use of BLC in DPLD. The relevant questions concerning different aspects of BLC were identified and circulated by e-mail among the members of the expert group. The questions were refined according to the suggestions of the experts. Next, the evidence relevant to each question was assimilated. The key points of evidence available with regard to each question were circulated. The suggestions of the members were incorporated after discussion in the e-mail group, and draft recommendations were framed. Finally, a face-to-face meeting was held (February 9, 2018; Coimbatore) where the evidence related to various questions was discussed; the draft recommendations were modified accordingly. A level of evidence and grade of recommendation was assigned to each recommendation according to a modified GRADE system (Table 1).[14] The final draft of the document was circulated among all expert members for suggestions and comments.

What are the indications of bronchoscopic lung cryobiopsy in diffuse parenchymal lung diseases? How is bronchoscopic lung cryobiopsy positioned vis-a-vis other procedures for the diagnosis of common diffuse parenchymal lung disease?

The indications of BLC are similar to those for SLB, namely the failure to arrive at a confident diagnosis of various technical aspects of BLC were framed. A literature search was conducted using PubMed and EMBASE databases. The expert group discussed the available evidence relevant to each question through e-mail and a face-to-face meeting, and arrived at a consensus. Results: The experts agreed that patients should be carefully selected for BLC after weighing the risks and benefits of the procedure. Where appropriate, consideration should be given to perform alternate procedures such as conventional transbronchial biopsy or subject the patient directly to a surgical lung biopsy. The procedure is best performed after placement of an artificial airway under sedation/general anesthesia. Fluoroscopic guidance and occlusion balloon should be utilized for positioning the cryoprobe to reduce the risk of pneumothorax and bleeding, respectively. At least four tissue specimens (with at least two of adequate size, i.e., ≥5 mm) should be obtained during the procedure from different lobes or different segments of a lobe. The histopathological findings of BLC should be interpreted by an experienced pulmonary pathologist. The final diagnosis should be made after a multidisciplinary discussion. Finally, there is a need for structured training for performing BLC. Conclusion: This position statement is an attempt to provide practical recommendations for the performance of BLC in DPLDs.

KEY WORDS: Bronchoscopy, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, interstitial lung disease, interventional pulmonology, lung biopsy, sarcoidosis, video-assisted thoracoscopic surgery
We suggest that the following investigations may preferably be obtained before performing BLC: arterial blood gases, and serology against human immunodeficiency virus.

The investigations required before performing BLC are as follows: [15,39,40]

- **Essential**
  - Complete blood count and coagulation profile
  - Serum creatinine
  - Spirometry and pulse oximetry
  - Electrocardiogram and echocardiography

- **Desirable**
  - Diffusion capacity of carbon monoxide (DLCO)
  - Arterial blood gases
  - Serology against human immunodeficiency virus and hepatitis B and C viruses.

**Recommendations**

- We recommend that the following investigations should be obtained before performing BLC in all patients: high-resolution CT chest, complete blood counts, clotting profile, serum creatinine, spirometry, pulse oximetry, electrocardiogram, and echocardiography (UPP).
- We suggest that the following investigations may preferably be obtained in most patients planned for BLC: DLCO, arterial blood gases, and serology against human immunodeficiency virus and hepatitis B and C viruses (UPP).

**Recommendations**

- We recommend that the following conditions be considered as absolute contraindications for BLC:

  - Systemic or local infection
  - Active bleeding diathesis
  - Active peptic ulcer disease
  - Pulmonary lobar consolidation
  - Acute exacerbation of interstitial lung disease (ILD)
  - Active pulmonary arterial hypertension
  - Active uncontrolled systemic hypertension
  - Uncontrolled diabetes mellitus
  - Uncontrolled metabolic acidosis
  - Thrush infection

**What are the contraindications of bronchoscopic lung cryobiopsy?**

The contraindications for BLC can be broadly divided into absolute and relative [15,39,40]. Subjects who are on antiplatelet or anticoagulation therapy should stop the drugs as per the standard guidelines [Table 4]. [41,42]
In to entry into the airway after performing We recommend that any antiplatelet and anticoagulant to

<table>
<thead>
<tr>
<th>Disease</th>
<th>Choice of procedure</th>
</tr>
</thead>
</table>
| Sarcoïdosis                    | The yield of conventional TBLB combined with endobronchial biopsy and transbronchial needle aspiration (either conventional or endobronchial ultrasound-guided) is sufficiently high for it to be considered as the investigation of choice for diagnosis. In nondiagnostic or unexpected cases, BLC can be considered, as it has been shown to have a high yield in patients with sarcoïdosis. If a definite diagnosis of a CTD can be made clinically, histological subtyping of the associated ILD is generally not useful, except for specific clinical scenarios (e.g., drug-induced ILD vs. disease-related ILD). In those with only auto-antibody positivity or a diagnosis of interstitial pneumonia with autoimmune features, lung biopsy (BLC or SLB) may be required.
| CTD-associated ILDs            | If a definite diagnosis of a CTD can be made clinically, histological subtyping of the associated ILD is generally not useful, except for specific clinical scenarios (e.g., drug-induced ILD vs. disease-related ILD). In those with only auto-antibody positivity or a diagnosis of interstitial pneumonia with autoimmune features, lung biopsy (BLC or SLB) may be required.
| HP                             | In an appropriate setting, the diagnosis of HP can also be established with bronchoaveolar lavage and conventional TBLB. BLC is another option when a confident diagnosis cannot be made on conventional modalities or when the presentation is that of a fibrotic DPLD.
| IPF and non-IPF idiopathic interstitial pneumonias (fibrotic DPLDs) | Lung biopsy is not required in those with “a definite UIP” pattern on HRCT and a clinical diagnosis of IPF. For others, either BLC or SLB is indicated. For differentiation of chronic HP from cellular NSIP, fibrotic NSIP and UIP, BLC is expected to have a reasonable yield (Figure 1). The most difficult challenge with BLC specimens is the differentiation of fibrotic NSIP and UIP, especially if sufficient samples from the subpleural area are not obtained. Further, it is known that areas showing NSIP may exist in the lungs of patients with IPF; thus a lung region with a UIP pattern may be missed in these patients due to sampling error. As BLC yields smaller samples than SLB, it may be more prone to sampling error. Despite these limitations, in one study, it was shown that BLC increases the diagnostic confidence in the multidisciplinary diagnosis of IPF, akin to SLB.

**Table 2: The indication of lung biopsy and the choice of procedures for the major subtypes of diffuse parenchymal lung diseases suspected on clinical and radiological findings**

**Table 3: Contraindications for performing bronchoscopic lung cryobiopsy**

**Absolute contraindications**
- High-risk for general anesthesia (American Society of Anesthesiologists category 4-6; if the procedure is planned under general anesthesia)
- Hemodynamic instability (hypotension or uncontrolled hypertension)
- Pulmonary hypertension (estimated pulmonary artery systolic pressure of >50 mmHg on echocardiography)
- Uncorrected bleeding diathesis (platelet count <50,000 cells/mm³, or INR >1.5)
- Severe hypoxemia (partial pressure of oxygen in arterial blood (PaO₂) <50 mmHg on room air)
- Pregnancy
- Diffuse lung disease with extensive cysts or bullae

**Relative contraindications**
- Hemoglobin <8 g/dL
- Reduced lung function (FVC <50% of predicted or 1.5 L or FEV₁ <0.8L, DLCO <30% of predicted)
- Body mass index >30 kg/m²
- INR: International normalized ratio, FVC: Forced vital capacity, DLCO: Diffusing capacity of lung for carbon monoxide, FEV₁: Forced expiratory volume in 1 s

**Should bronchoscopic lung cryobiopsy be performed with an artificial airway in place or without a protected airway?**

- American Society of Anesthesiologists category 4–6; hemodynamic instability; pulmonary hypertension; uncorrected bleeding diathesis; significant hypoxemia; pregnancy; cystic DPLDs (UPP)
- We suggest that the following be considered as relative contraindications for BLC: hemoglobin <8 g/dL; reduced lung function; DLCO <30% of predicted obesity (UPP)
- We recommend that any antiplatelet and anticoagulant medications be stopped as per the standard guidelines (UPP).

**Airway (AA). Most studies describe the use of an endotracheal tube (ET), laryngeal mask airway (LMA), or the rigid bronchoscope [Table 5]. There are, however, a few studies that have described BLC without an AA. Although the yield of BLC in these studies (66%-98%) is similar to that with the use of AA (51%-98%), certain aspects need consideration. First, the use of an AA allows rapid re-entry into the airway after performing the biopsy without having to renavigate through the nasal or oral cavity and the vocal cords. Second, it also obviates the risk of the frozen distal end of the cryoprobe getting adhered to the upper tracheal wall or a resection of the tracheal ring, at the event of significant bleeding. Fourth, if an AA is not used, the patient has to be maintained in a lighter plane of anesthesia that may be associated with vigorous coughing, thus increasing the chance of slippage of the occlusion balloon (OB).

**Should bronchoscopic lung cryobiopsy be performed with an artificial airway in place or without a protected airway?**

- Use of an endotracheal tube (ET), laryngeal mask airway, or rigid bronchoscope? No head-to-head study has compared the outcomes of BLC with or without the placement of an artificial airway.

**Should bronchoscopic lung cryobiopsy be performed with an artificial airway in place or without a protected airway?**

- Use of an endotracheal tube (ET), laryngeal mask airway, or rigid bronchoscope? No head-to-head study has compared the outcomes of BLC with or without the placement of an artificial airway.

- Use of an endotracheal tube (ET), laryngeal mask airway, or rigid bronchoscope? No head-to-head study has compared the outcomes of BLC with or without the placement of an artificial airway.
Table 4: Standard recommendations for peri-procedure use of anticoagulant and antiplatelet agents

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticoagulant drugs</td>
<td></td>
</tr>
<tr>
<td>Warfarin</td>
<td>Should be stopped 5 days before procedure. INR should be &lt;1.5 on the day of procedure</td>
</tr>
<tr>
<td>Low-molecular weight heparin</td>
<td>Stop at least 24 h before procedure. Resume 24 h after the procedure</td>
</tr>
<tr>
<td>Unfractionated heparin</td>
<td>Discontinue 8 h before the procedure. Resume 24 h after the procedure</td>
</tr>
<tr>
<td>(intravenous)</td>
<td>Should be stopped 2-4 h before the procedure</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>Should be stopped at least 2 days before the procedure. Resume 24 h after the procedure</td>
</tr>
<tr>
<td>Rivaroxaban, edoxaban, apixaban</td>
<td>Discontinue 8 h before the procedure</td>
</tr>
<tr>
<td>Antiplatelet drugs</td>
<td></td>
</tr>
<tr>
<td>Tirofiban</td>
<td>Discontinue 8 h before the procedure</td>
</tr>
<tr>
<td>Eptifibatide</td>
<td>Discontinue 8 h before the procedure</td>
</tr>
<tr>
<td>Abciximab</td>
<td>Discontinue 24 h before the procedure</td>
</tr>
<tr>
<td>Aspirin (low-dose)</td>
<td>Discontinue 3 days prior to the procedure</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>Withhold 7 days before the procedure</td>
</tr>
<tr>
<td>Prasugrel</td>
<td>Withhold 7 days before the procedure</td>
</tr>
<tr>
<td>Ticlopidine</td>
<td>Withhold 10-14 days before the procedure</td>
</tr>
</tbody>
</table>

**Recommendations**

- We recommend that an AA be used while performing BLC (2A).
- We suggest that an ET or rigid bronchoscope may be preferred over LMA (UPP).

**What type of sedation/anesthesia should be used for performing bronchoscopic lung cryobiopsy?**

No study has investigated the effect of different levels of sedation on the yield and safety of BLC. There appears no difference in the diagnostic yield between studies using conscious sedation (66%–98%)

or deep sedation/general anesthesia (GA) (51%–98%).

The rate of complications was also similar in studies, independent of the level of sedation, or the use of GA. The choice of the depth of sedation (conscious/moderate sedation, deep sedation, or GA) mainly depends on the type of AA used. Conscious/moderate sedation has been used in the absence of an AA. Any level of sedation (moderate/deep/GA) can be used with ET/LMA, while rigid bronchoscopy is uniformly performed under deep sedation/GA.

**Recommendations**

- We recommend that BLC should be performed under either moderate (or conscious) sedation, deep sedation, or GA (2A).
- We recommend that if rigid bronchoscopy is used, deep sedation or GA should be employed (2A).

**Should an occlusion balloon be routinely used during bronchoscopic lung cryobiopsy?**

Several studies have described the prophylactic placement of an OB in the segmental or lobar bronchus. The OB is inflated immediately after performing each biopsy to avoid spillage of blood to other parts of the airway, in case massive bleeding occurs. Further, the tamponade effect produced by the OB helps in controlling the bleeding. Different types of OBs have been used in various studies: Balloon occlusion catheter (Fogarty; Edwards Lifesciences, Irvine, CA, USA), endobronchial blocker (Arndt; Cook Medical, Bloomington, IN, USA), and percutaneous transluminal angioplasty balloon catheter (ATB Advance, Cook Medical). The usual size of the OB used in bronchial blockade is 5–7 Fr.

In studies describing the use of OB, the incidence of bleeding has ranged from 1.4% to 30%.

Higher bleeding rates have been reported in studies that have not described the use of OB (up to 78% moderate-to-severe bleeding). Massive bleeding after biopsy entails the risk of immediate hypoxemia and asphyxia, especially if it floods the contralateral bronchial tree. It may also trigger an acute exacerbation of the underlying ILD, resulting in need for prolonged ventilation.

The use of an OB reduced the risk of moderate-to-severe bleeding (bleeding incidence, 1.8% vs. 35.7%; adjusted odds ratio [OR], 95% confidence interval [CI]: 0.02 [0.001–0.18]) in one study.

Further, two reports have described the introduction of the prophylactic use of OB into their procedural protocol after encountering serious bleeding.

It is important to ensure the correct placement of the balloon and prevent its displacement and rupture while performing BLC. There is a theoretically higher chance of the balloon getting damaged when placed adjacent to the probe in the segmental bronchus compared to its placement in the lobar bronchus.

**Recommendation**

- We recommend that an OB should be used while performing BLC (2A).

**Should fluoroscopy be used for guiding bronchoscopic lung cryobiopsy?**

All but three published studies on BLC have reported the use of fluoroscopy during the procedure (Table 4).

Fluoroscopy is used to facilitate the appropriate placement of the cryoprobe tip before performing BLC. This is important because of several reasons. If the probe is blindly advanced up to the pleura, it may increase the risk of pneumothorax. A retrospective study found a reduced risk of pneumothorax with the use of fluoroscopy (pneumothorax incidence, 5.9% vs. 20.9%) (adjusted OR [OR], 95% CI]: 0.26 [0.07–0.94]).

There are several other advantages of using fluoroscopy during BLC. The appropriate placement of cryoprobe “closer to” the periphery is essential for sampling the subpleural parenchyma, which is especially useful in...
### Table 5: Studies describing the use of bronchoscopic lung cryobiopsy and their technical aspects in the diagnosis of diffuse parenchymal lung diseases

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>$n$</th>
<th>Artificial airway</th>
<th>Level of sedation/ anesthesia</th>
<th>Occlusion balloon</th>
<th>Probe</th>
<th>Fluoroscopy</th>
<th>Diagnostic yield</th>
<th>Pneumothorax, %</th>
<th>Bleeding, %</th>
<th>Death, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Babiak et al., (2009)</td>
<td>41</td>
<td>ET</td>
<td>Deep sedation</td>
<td>No</td>
<td>2.4</td>
<td>Yes</td>
<td>95</td>
<td>49</td>
<td>0 (severe)</td>
<td>NA</td>
</tr>
<tr>
<td>Pajares et al., (2010)</td>
<td>10</td>
<td>ET</td>
<td>Sedation</td>
<td>No</td>
<td>2.4</td>
<td>Yes</td>
<td>50</td>
<td>0</td>
<td>60 (mild-moderate)</td>
<td>0</td>
</tr>
<tr>
<td>Kropski et al., (2013)</td>
<td>25</td>
<td>ET</td>
<td>Moderate sedation</td>
<td>No</td>
<td>1.9</td>
<td>Yes</td>
<td>80</td>
<td>0</td>
<td>4</td>
<td>NA</td>
</tr>
<tr>
<td>Casoni et al., (2014)</td>
<td>69</td>
<td>RB</td>
<td>Deep sedation</td>
<td>Yes</td>
<td>2.4</td>
<td>Yes</td>
<td>91</td>
<td>28</td>
<td>1.4</td>
<td>1</td>
</tr>
<tr>
<td>Fruchter et al., (2014)</td>
<td>75</td>
<td>None</td>
<td>Conscious sedation</td>
<td>No</td>
<td>2.4</td>
<td>Yes</td>
<td>98</td>
<td>2.6</td>
<td>4 (moderate)</td>
<td>NA</td>
</tr>
<tr>
<td>Griff et al., (2014)</td>
<td>52</td>
<td>None</td>
<td>Sedation</td>
<td>No</td>
<td>1.9</td>
<td>Yes</td>
<td>79</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pajares et al., (2014)</td>
<td>39</td>
<td>ET</td>
<td>Deep sedation</td>
<td>No</td>
<td>2.4</td>
<td>Yes</td>
<td>74</td>
<td>7.7</td>
<td>87.2 (mild-moderate)</td>
<td>NA</td>
</tr>
<tr>
<td>Gershman et al., (2015)</td>
<td>139</td>
<td>ET</td>
<td>General anesthesia</td>
<td>No</td>
<td>2.4</td>
<td>Yes</td>
<td>95</td>
<td>4.9</td>
<td>0 (severe)</td>
<td>NA</td>
</tr>
<tr>
<td>Hernández-González et al., (2015)</td>
<td>33</td>
<td>ET</td>
<td>GA</td>
<td>Yes</td>
<td>1.9</td>
<td>Yes</td>
<td>79</td>
<td>0</td>
<td>6 (mild-moderate)</td>
<td>NA</td>
</tr>
<tr>
<td>Cascarini et al., (2014)</td>
<td>69</td>
<td>RB</td>
<td>Sedation</td>
<td>No</td>
<td>1.9</td>
<td>Yes</td>
<td>79</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fruchter et al., (2014)</td>
<td>100</td>
<td>ET</td>
<td>GA</td>
<td>Yes</td>
<td>1.9</td>
<td>Yes</td>
<td>79</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pajares et al., (2014)</td>
<td>39</td>
<td>ET</td>
<td>Conscious sedation</td>
<td>No</td>
<td>2.4</td>
<td>Yes</td>
<td>74</td>
<td>7.7</td>
<td>87.2 (mild-moderate)</td>
<td>NA</td>
</tr>
<tr>
<td>Haggmeier et al., (2016)</td>
<td>32</td>
<td>RB (7)/ET (25)</td>
<td>GA (7)/sedation (25)</td>
<td>No</td>
<td>NR</td>
<td>Yes</td>
<td>72</td>
<td>19</td>
<td>78 (moderate-severe)</td>
<td>0</td>
</tr>
<tr>
<td>Haggmeier, (2016)</td>
<td>19</td>
<td>ET</td>
<td>Sedation</td>
<td>No</td>
<td>1.9</td>
<td>Yes</td>
<td>78</td>
<td>26</td>
<td>79 (moderate-severe)</td>
<td>1</td>
</tr>
<tr>
<td>Pourabdollahi et al., (2016)</td>
<td>41</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
<td>2.4</td>
<td>Yes</td>
<td>66</td>
<td>20</td>
<td>2 (moderate-severe)</td>
<td>0</td>
</tr>
<tr>
<td>Almeida et al., (2017)</td>
<td>100</td>
<td>RB</td>
<td>GA</td>
<td>Yes</td>
<td>2.4</td>
<td>Yes</td>
<td>82</td>
<td>18</td>
<td>3 (moderate)</td>
<td>1</td>
</tr>
<tr>
<td>Bango-Alvarez et al., (2017)</td>
<td>106</td>
<td>None</td>
<td>Moderate sedation</td>
<td>No</td>
<td>1.9</td>
<td>Yes</td>
<td>86</td>
<td>4.7</td>
<td>16 (moderate)</td>
<td>0</td>
</tr>
<tr>
<td>DiBardino et al., (2017)</td>
<td>25</td>
<td>ET (4)/LMA (21)</td>
<td>GA</td>
<td>No</td>
<td>1.9/2.4</td>
<td>Yes (10, no (15)</td>
<td>76</td>
<td>8</td>
<td>12 (moderate-severe)</td>
<td>NA</td>
</tr>
<tr>
<td>Kronborg-White et al., (2017)</td>
<td>38</td>
<td>ET</td>
<td>GA</td>
<td>Yes</td>
<td>1.9/2.4</td>
<td>Yes</td>
<td>74</td>
<td>26</td>
<td>16 (moderate)</td>
<td>0</td>
</tr>
<tr>
<td>Maryčo et al., (2017)</td>
<td>90</td>
<td>RB</td>
<td>GA</td>
<td>Yes</td>
<td>2.4</td>
<td>Yes</td>
<td>71</td>
<td>24.4</td>
<td>5.5 (moderate)</td>
<td>0</td>
</tr>
<tr>
<td>Ravaglia et al., (2017)</td>
<td>46</td>
<td>RB</td>
<td>Deep sedation</td>
<td>Yes</td>
<td>2.4</td>
<td>Yes</td>
<td>69/96</td>
<td>16</td>
<td>8.7 (mild-severe)</td>
<td>0</td>
</tr>
<tr>
<td>Sripratsart et al., (2017)</td>
<td>74</td>
<td>ET/LMA</td>
<td>GA</td>
<td>No</td>
<td>1.9/2.4</td>
<td>Yes</td>
<td>88</td>
<td>6.8</td>
<td>100 (4 moderate-severe)</td>
<td>3</td>
</tr>
<tr>
<td>Ussavarungsi et al., (2017)</td>
<td>74</td>
<td>ET</td>
<td>Deep sedation</td>
<td>Yes</td>
<td>1.9</td>
<td>Yes</td>
<td>51</td>
<td>1.4</td>
<td>22</td>
<td>0</td>
</tr>
<tr>
<td>Dhoooria et al., (2018)</td>
<td>128</td>
<td>None (5)/RB (123)</td>
<td>Conscious sedation</td>
<td>Yes (114)/</td>
<td>1.9</td>
<td>Yes (85), no (43)</td>
<td>78</td>
<td>10.9</td>
<td>15.6</td>
<td>4</td>
</tr>
<tr>
<td>Lentz et al., (2018)</td>
<td>104</td>
<td>ET</td>
<td>Deep sedation</td>
<td>Yes/no</td>
<td>1.9</td>
<td>Yes</td>
<td>68</td>
<td>2.9</td>
<td>3.8 (moderate-severe)</td>
<td>0</td>
</tr>
</tbody>
</table>

*ET: Endotracheal tube, GA: General anesthesia, LMA: Laryngeal mask airway, NA: Not available, RB: Rigid bronchoscope*
the differentiation of IPF and fibrotic NSIP. In such a situation, when an attempt is made to sample the subpleural parenchyma, the cryobiopsy specimen would contain fragments of pleura. However, the presence of pleura does not necessarily mean that the patient will develop a pneumothorax, although the risk is higher. Thirdly, inadvertent proximal sampling in the absence of fluoroscopy may lead to disruption of major bronchial vessels, resulting in significant bleeding. Finally, fluoroscopic guidance may help in screening for pneumothorax immediately after each biopsy.

The positioning of cryoprobe is a trade-off between the risk of pneumothorax, on the one hand (the probe placed too close to the pleura), and the increased risk of bleeding along with the chances of potentially missing the subpleural lung parenchyma, on the other (when the probe is placed too proximally). A large study (n = 297) with a large proportion (39%) of cases diagnosed with usual interstitial pneumonia (UIP)/NSIP (where peripheral lung sampling is most important) has described the placement of cryoprobe about 10 mm away. The study reported a diagnostic yield of 83% with 20% of subjects having a pneumothorax. Probe placement 15–20 mm from the pleura, described in another study, may be associated with a lesser incidence of pneumothorax (3%) but may potentially miss out on subpleural sampling (diagnostic yield, 68%) and may be associated with an increased bleeding risk (4%).

Recommendations
- We recommend that fluoroscopic guidance should be used during the performance of BLC, wherever available (2A).
- We suggest that the cryoprobe may be placed about 10 mm from the pleura for performing BLC (3B).

What is the size of the cryoprobe that should be used for bronchoscopic lung cryobiopsy?
Either a 1.9-mm or 2.4-mm cryoprobe has been used in different studies of BLC. There is no human study that has compared the yield and safety of these two probes. In an in vivo porcine model, the 2.4-mm cryoprobe yielded a larger sample compared to the 1.9-mm probe if the same activation time was used. The diameter of the biopsy was similar with an activation time of 3 s for the 2.4-mm probe and 5 s for the 1.9-mm probe. However, appropriate placement of the 2.4-mm probe may be more difficult as it may get obstructed by a bronchial bifurcation while being advanced into the pulmonary parenchyma. There is also a higher risk of bleeding due to the rupture of larger bronchial vessels due to an inadvertent proximal placement (in the absence of fluoroscopy). It may be difficult to advance the larger probe into the lung periphery, especially in obese individuals and in those with extensive lung fibrosis. In view of these practical concerns, pending comparative studies of safety and yield between these probes, the 1.9-mm probe appears preferable.

Recommendations
- We suggest that a 1.9-mm probe may be preferred over the 2.4-mm probe for performing BLC (UPP).

Which cryogen and what activation/freezing time should be used for bronchoscopic lung cryobiopsy?
Two different cryogens, i.e., nitrous oxide and carbon dioxide, have been used for BLC. Both the gases reach temperatures below −50°C that is sufficient for BLC. Carbon dioxide may be less expensive and more readily available. Almost all studies on BLC have described the freezing time from 3 to 6 s. There is no comparative human study that compares different freezing/probe activation times. In an in vivo porcine model study (using carbon dioxide as cryogen), no difference in the histological accessibility of specimen or risk of bleeding was observed between shorter (2–4 s) and longer (4–6 s) freezing times with the 1.9-mm probe. In another in vivo animal study in sheep, increasing freezing time led to an increase in the BLC cross-sectional area (6.5, 7.1, 9.0, and 15.7 mm² with 3, 4, 5, and 6 s, respectively). However, the risk of bleeding and pneumothorax was higher with a 5–6 s freezing time (the cryogen used was carbon dioxide). Further, the use of a 5-s activation time with a carbon dioxide probe resulted in excessive resistance encountered during withdrawal of the probe. As nitrous oxide achieves a lower minimum temperature (−89°C) compared to carbon dioxide (−79°C), cooling occurs faster, with a shorter freezing time.

Recommendations
- We suggest that a freezing time of 3 s with nitrous oxide cryogen (or 4 s with carbon dioxide cryogen) may be used initially (UPP).
- We suggest that if a specimen of adequate size (described later) is not obtained with this activation time, the freezing time may be increased up to 6 s (UPP).

How many specimens should be obtained?
Studies on BLC have described obtaining 1–6 specimens. A recent study evaluated the cumulative yield of increasing number of biopsies and reported a yield of 96% when two biopsies were obtained from different segments. However, this study was performed at a highly experienced center using rigid bronchoscopy, deep sedation, a 2.4-mm probe (freezing time, 5 s), Fogarty balloon, and fluoroscopy. The size of the first and second biopsies was 37.8 and 28.1 mm², respectively. Such a result may not be achievable at all centers. A retrospective study found higher diagnostic yields with increasing number of biopsies (adjusted OR [95% CI], 2.17 [1.29–3.67]). In this study, the diagnostic yield was 90.7% with four or more specimens compared to 75.3% with 1–3 specimens (unpublished data, P = 0.055). There is theoretically an increased risk of complications with increasing number of biopsies.

Recommendations
- We recommend that at least four tissue specimens (with at least two of adequate size [see later]) be obtained during BLC (3A).
Which lobes should be selected for taking the tissue sample during bronchoscopic lung cryobiopsy? How many lobes and segments should be sampled?

The conventional practice with SLB is to sample at least two different lobes. This is because discordant histopathologic features may be found in different lung areas (e.g., patients with UIP can show areas of NSIP in a significant proportion of cases). Sampling of two lobes was also found to increase the diagnostic yield of BLC in one study (91% with two lobes vs. 73% with one lobe), while it did not affect the yield in another. However, in both the studies, the number of subjects in whom two lobes were sampled was small.

Although it would be ideal to obtain BLC from two different lobes, it may not be always feasible. Certain points merit consideration. The lower lobe is generally preferred for BLC because of the technical ease and the lower lobar predominance of abnormalities in most DPLDs. Further, the dependent position of the lower lobe ensures that even if bleeding occurs, it remains confined to the same lobe. Sampling the middle lobe may be associated with a higher chance of pneumothorax as the bronchi in this lobe may be directed toward the oblique fissure. Although debatable, biopsies from the middle lobe and lingula may yield nonspecific interstitial changes. Finally, sampling the upper lobe may be technically difficult, with an increased risk of slippage of the OB and consequent increased risk of bleeding. If a single lobe is sampled, two BLC samples taken from the same segment result in a lower yield (78%) than two samples taken from different segments of the same lobe (96%).

Recommendations

- We suggest that it is preferable to obtain samples from two lobes (UPP).
- We recommend that BLC samples should be obtained from different segments of the lower lobe, if a single lobe is being sampled (2A).
- We suggest that upper lobe sampling may be attempted after gaining sufficient experience in the technique (UPP).

What are the complications of bronchoscopic lung cryobiopsy?

The complications of BLC include pneumothorax (pooled estimate [95% CI], 9.5% [5.9%–14.9%], moderate-severe endobronchial bleeding [pooled estimate [95% CI], 4.9% [2.2%–10.7%]), and acute exacerbation of the underlying ILD, need for prolonged mechanical ventilation, prolonged hypoxemia, postprocedure infection/fever, and death (0.7% [0.4%–1.2%]). Other uncommon complications include pneumomediastinum and subcutaneous emphysema. The management of pneumothorax includes observation, oxygen therapy, single time aspiration, or intercostal drainage, according to the size of the pneumothorax and the patient's symptoms. The management of endobronchial bleeding includes suction, instillation of ice-cold saline, and/or epinephrine, and prolonged (>3 min) inflation of the OB to block the biopsied segment/lobe. If these measures fail, intubation of the contralateral side with the rigid bronchoscope or endotracheal tube to isolate the bleeding lung may be required. Patients may also develop acute exacerbation of the underlying ILD either due to BLC per se or due to the occurrence of airway bleeding.

What investigations and monitoring are required in the postprocedure period? Can bronchoscopic lung cryobiopsy be performed as a daycare procedure or hospitalization is required?

Chest radiograph is required to detect a pneumothorax in the postoperative period (generally 2–3 h after the procedure). Chest ultrasound performed by trained pulmonologists for the detection of pneumothorax following BLC has a sensitivity and specificity of 90% and 94%, respectively, and is superior to a chest radiograph. In a meta-analysis, chest ultrasonography had a pooled sensitivity and specificity of 78.6% (95% CI, 68.1–98.1) and 98.4% (95% CI, 97.3–99.5), respectively, for the detection of pneumothorax; while the sensitivity and specificity of chest radiography was 39.8% (95% CI, 29.4–50.3) and 99.3% (95% CI, 98.4–100), respectively. The working group acknowledged that chest ultrasound performed by trained operators, although more sensitive, may be difficult to obtain at all centers. Hence, a chest radiograph is a good alternative especially when performed on two separate occasions. For screening immediately after the procedure, fluoroscopy itself may be utilized.

If the BLC procedure is uncomplicated (no or mild bleeding, no postprocedure hypoxemia, and the absence of pneumothorax), the patient can be discharged after 4–6 h. A follow-up by a phone call at 24 h has been described in one study. In case of a complication (moderate-severe bleeding, intra- or post-procedure hypoxemia, pneumothorax), the patient requires a longer observation with monitoring of vital parameters and appropriate management. As complications of BLC can be delayed, easy access to health services is advisable even after discharge.

Recommendations

- We recommend that a chest radiograph (or fluoroscopic screening) or a thoracic ultrasound should be performed immediately after the procedure (2A).
- We suggest that in case of an uncomplicated procedure, the patient can be discharged after 6 h of observation (3B).
- We recommend that in case of a complicated procedure, the patient should be managed in the hospital for as long as is required (UPP).

What is the minimum size of bronchoscopic lung cryobiopsy required for histological analysis? How should the bronchoscopic lung cryobiopsy histopathology be interpreted and reported?

The size of the biopsy obtained may influence the diagnostic yield. In a study on fibrosing DPLDs, diagnostic cryobiopsies had a larger total size than nondiagnostic biopsies...
Dhooria, et al.: Position statement on BLC

Thus, in general, a total surface area of ≥40 mm² should be targeted. Visually adequate BLC specimens are generally 5 mm or more in diameter, much bigger than the 1–3 mm diameter specimens obtained with conventional TBLB. A 5-mm diameter corresponds to a surface area of about 20 mm². Thus, two such specimens would represent a total surface area of 40 mm². A large biopsy sample helps in the identification of different histological features (e.g., patchy fibrosis, honeycombing, and fibroblastic foci typical of a usual interstitial pneumonia pattern) in the same specimen [Figure 1]. In other cases, the different patterns may be identified in different biopsy samples [Figure 2]. It is essential that BLC specimens are reported by a pathologist with experience in DPLDs. Reporting is best done in a systematic way so that interpretation can be made with greater confidence [Table 6].

Certain characteristics of the biopsy specimen should also be routinely reported [Table 6]. The maximum dimension (diameter/length) and a rough estimate of the number of alveoli in each specimen (>100 is generally considered adequate) are important parameters for judging the adequacy of specimen. The presence of a sufficient number of terminal bronchioles is important if airway-centric pathology (such as bronchiolitis or HP) is a consideration [Figure 3]. The presence of larger airways, cartilage, or large vessels represents proximal sampling and can provide important feedback to the bronchoscopist. The presence of pleura represents subpleural sampling, which may be especially useful in diagnosing IPF. Freezing artifacts are rare in contrast to their frequent occurrence with surgical frozen sections. Artifacts in the form of implantation of bronchiolar epithelium in the alveolar tissue and intra-alveolar hemorrhage and/or proteinaceous fluid may appear due to the thrusting of the probe through the bronchi and the trauma of the biopsy process, respectively. Crush artifacts may be present if improper handling of the specimen is done, while collapsed air spaces may be encountered due to poor permeation of fixative if the BLC specimen is not shaken properly in the preservative formalin solution [Figure 4]. It is also important that the BLC sample is thawed in air. If thawing is performed in normal saline, it should be done only for a few seconds, and the sample should then immediately be transferred to formalin. Prolonged thawing in saline may lead to degeneration of antigens and DNA, which may hamper future immunohistochemical and molecular studies.

<table>
<thead>
<tr>
<th>Gross description</th>
<th>Microscopic description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of fragments</td>
<td>For adequacy</td>
</tr>
<tr>
<td>Number of terminal bronchioles</td>
<td>Number of fragments</td>
</tr>
<tr>
<td>Number of alveoli (rough estimate)</td>
<td>Number of terminal bronchioles</td>
</tr>
<tr>
<td>For feedback to the operator</td>
<td>Number of alveoli (rough estimate)</td>
</tr>
<tr>
<td>Bronchial cartilage/ large airway</td>
<td>For feedback to the operator</td>
</tr>
<tr>
<td>Large vessel</td>
<td>Pleura</td>
</tr>
<tr>
<td>Artifacts</td>
<td>Artifacts</td>
</tr>
<tr>
<td>Alveolar hemorrhage/proteinaceous fluid</td>
<td>Alveolar hemorrhage/proteinaceous fluid</td>
</tr>
<tr>
<td>Implantation of bronchiolar epithelium in alveolated areas</td>
<td>Accessories</td>
</tr>
<tr>
<td>Freezing artifacts</td>
<td>Crush artifacts</td>
</tr>
<tr>
<td>Crush artifacts</td>
<td>Collapsed alveolar spaces</td>
</tr>
<tr>
<td>Collapsed alveolar spaces</td>
<td>For diagnosis</td>
</tr>
<tr>
<td>For diagnosis</td>
<td>Morphologic description</td>
</tr>
<tr>
<td>Morphologic description</td>
<td>Histopathological diagnosis</td>
</tr>
<tr>
<td>Histopathological diagnosis</td>
<td>Diagnostic confidence: Definite/probable/possible/nondiagnostic</td>
</tr>
</tbody>
</table>

Figure 2: Usual interstitial pneumonia was diagnosed after considering the findings in multiple bronchoscopic lung cryobiopsy specimens (a). The individual specimens showed normal lung parenchyma and fibrous scarring (b), honeycombing (c), and fibroblastic foci (d) [H and E, (a) ×40, (b) ×100, and (c) ×200, respectively].

Figure 3: Features of hypersensitivity pneumonitis in different bronchoscopic lung cryobiopsy specimens. Peribronchial lymphomononuclear cell infiltrate with isolated giant cells (a and b), ill-formed interstitial granulomas (c), and distortion of the architecture, bridging fibrosis with peribronchiolar inflammation and giant cells indicative of usual interstitial pneumonia-like pattern in chronic hypersensitivity pneumonitis (d) [H and E, (a) ×100, (b) ×200, (c) ×100, and (d) ×100, respectively].

Lung India • Volume 36 • Issue 1 • January-February 2019
We recommend that the target is to obtain a BLC specimen of at least 5 mm diameter (2A).

- We recommend that BLC specimens should be studied with experience in managing endobronchial bleeding, expertise in conventional TBLB procedures, and plateaued after about 70 procedures. Although it is difficult to define objective criteria, a bronchoscopist having good expertise in conventional TBLB (about 50 procedures), with experience in managing endobronchial bleeding, should be able to quickly learn the technique.

Recommendations

- We recommend that all clinical, radiologic, and pathologic findings should be discussed during a multidisciplinary team meeting to arrive at an MDD diagnosis (1A).
- We recommend that a diagnostic confidence level should be assigned to the MDD diagnosis (UPP).

How is the information from bronchoscopic lung cryobiopsy incorporated into multidisciplinary discussion for the diagnosis of diffuse parenchymal lung diseases?

The information from BLC is incorporated into the MDD similar to that of SLB. BLC may be prone to sampling error due to its smaller size and sampling from one lobe. However, it should not be forgotten that even SLB with its higher diagnostic yield may still be associated with sampling errors. The BLC procedure is essentially a trade-off between the higher diagnostic yield of SLB and the lower complication rate (including mortality) of BLC. The information from BLC should not be viewed in isolation, but rather combined with clinical and radiologic information to arrive at a reasonable consensus during MDD. At this stage, it is also important to assign some level of confidence to the final diagnostic impression.

Recommendations

- We recommend that an experience of 50 conventional TBLB procedures, an experience in management of endobronchial bleeding, and the availability of expertise in intubation are the essential requirements for the performance of BLC (UPP).

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES


48. Hagmeyer L, Theegarten D, Trem M, Priegnitz C, Raderath W. Validation of transbronchial cryobiopsy in interstitial lung disease - interim analysis of a prospective trial and critical review of the literature. Sarcoidosis Vasc Lung India • Volume 36 • Issue 1 • January-February 2019
Dhoria, et al.: Position statement on BLC